Mobile

Open label pilot study to treat women with chronic urinary retention or voiding dysfunction due to a primary disorder of sphincter relaxation (Fowler’s syndrome) with outpatient urethral sphincter inj...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-004858-33

Open label pilot study to treat women with chronic urinary retention or voiding dysfunction due to a primary disorder of sphincter relaxation (Fowler’s syndrome) with outpatient urethral sphincter injections of botulinum toxin A (BoNT-A)

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To investigate if urethral sphincter injections of botulinum toxin A can A) restore voiding in those with complete retention (the inability to pass any urine from the bladder normally). B) improve flow rates by more than 50% in those with incomplete bladder emptying

Critère d'inclusion

  • Primary abnormality of the urethral sphincter or Fowlers Syndrome

Liens